You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • OP0098 Remission and maintenance of efficacy in a phase 2b study of vobarilizumab, an anti-interleukin 6 receptor nanobody, in patients with moderate-to-severe rheumatoid arthritis despite treatment with methotrexate

Article metrics

Article menu

Download PDFPDF

Oral Presentations
Progress in biological treatment of RA
OP0098 Remission and maintenance of efficacy in a phase 2b study of vobarilizumab, an anti-interleukin 6 receptor nanobody, in patients with moderate-to-severe rheumatoid arthritis despite treatment with methotrexate
Free

 

Online download statistics by month:

Online download statistics by month: June 2017 to March 2024

AbstractFullPdf
Jun 20171102
Jul 20172002
Aug 20172600
Sep 20172403
Oct 20172404
Nov 20171800
Dec 2017800
Jan 20184402
Feb 20181800
Mar 20181400
Apr 20182603
May 20181803
Jun 2018600
Jul 20181201
Aug 20181000
Sep 2018401
Oct 2018601
Nov 20181002
Dec 20181803
Jan 2019603
Feb 2019602
Mar 20191805
Apr 2019402
May 2019203
Jun 2019603
Jul 2019204
Aug 2019704
Sep 2019400
Oct 2019202
Nov 2019405
Dec 2019202
Jan 2020100
Feb 2020603
Mar 2020401
Apr 2020002
May 20201404
Jun 2020803
Jul 20201002
Aug 20201206
Sep 2020802
Oct 2020400
Nov 2020804
Dec 20201003
Jan 2021803
Feb 2021002
Mar 20212007
Apr 2021603
May 2021002
Jun 2021007
Jul 2021001
Sep 2021007
Oct 20213019
Nov 202116018
Dec 2021902
Jan 20221001
Feb 20221203
Mar 2022802
Apr 20221203
May 20221109
Jun 20222606
Jul 20221401
Aug 2022804
Sep 20221605
Oct 2022405
Nov 20221208
Dec 2022500
Jan 2023801
Feb 2023803
Mar 20231601
Apr 2023601
May 2023305
Jun 20231703
Jul 2023102
Aug 2023202
Sep 2023701
Oct 20232401
Nov 2023100
Dec 20231401
Jan 20241603
Feb 20247706
Mar 20241107
Total8760247